Replies to post #78747 on $heff's $tation of $tocks & $olid DD

[Kung Fu Panda]

$SYN - The $heff effect! For once I bought in before you at $2.79. I just knew you were going there too!

[buckiii2]

I think it is the 29th? SYN

[ridinbulls]

SYN...in addition to the catalyst for Trimesta results on April 26th, they will also be disclosing results from the baby baboon trial for Pertussis within the next few weeks. This was mentioned by the CEO during his presentation at the Roth conference. If you listen to the presentation one would be heavily inclined to believe the results are positive based on his comment that he said," I can't discuss results but lets just say I'm smiling"

[bra1loga]

SYN looking great Sheff! I have one of those feelings that something big is going to happen here :)

[trade2much]

SYN <annotated chart, bullish imo>

[buckiii2]

Synthetic Biologics Announces Rhonda Voskuhl, M.D., to Present Trimesta™ Phase II Multiple Sclerosis Clinical Trial Results at the 2014 AAN Annual Meeting
ROCKVILLE, Md., Feb. 10, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Rhonda Voskuhl, M.D., the lead investigator of the Phase II clinical trial evaluating the Company's oral estriol product candidate, Trimesta™, for the treatment of relapsing-remitting multiple sclerosis (MS), will present topline results at the American Academy of Neurology's (AAN) 66th Annual Meeting in Philadelphia. The abstract titled, A Combination Trial of Estriol Plus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis, will be presented as part of the AAN Emerging Science program during two sessions, as follows:

MS and CNS Inflammatory Disease: Novel Therapeutics
Presentation: 003
Event Date: Tuesday, April 29, 2014
Presentation Time: 3:45 p.m. (ET)

Emerging Therapeutic Advances in Multiple Sclerosis
Presentation: 002
Event Date: Wednesday, April 30, 2014
Presentation Time: 5:35 p.m. (ET)

Trimesta™ (oral estriol) is being evaluated in combination with Copaxone® (glatiramer acetate injection) in a randomized, double-blind, placebo-controlled Phase II clinical trial for the treatment of relapsing-remitting MS in women. Lead Principal investigator, Rhonda Voskuhl, M.D., Professor, Department of Neurology, Jack H. Skirball Chair in Multiple Sclerosis Research and Director, Multiple Sclerosis Program at University of California, Los Angeles (UCLA) School of Medicine, along with investigators at 14 other U.S. centers, administered either Trimesta™ (8 milligrams orally per day) in combination with Copaxone® (20 milligrams per day), or a placebo plus Copaxone® to patients randomized in the trial.

Patients in this Phase II relapsing-remitting MS trial completed their final 24-month visit during January 2014. The primary outcome measure for the study is the annualized rate of relapse between the placebo and treated groups, an accepted FDA-approvable endpoint in MS. The clinical trial is supported by grants exceeding $8 million, awarded primarily by the National Multiple Sclerosis Society (NMSS) in partnership with the NMSS's Southern California chapter, and the National Institutes of Health.http://www.syntheticbiologics.com/2014-02-10-Synthetic-Biologics-Announces-Rhonda-Voskuhl-M-D-to-Present-Trimesta-Phase-II-Multiple-Sclerosis-Clinical-Trial-Results-at-the-2014-AAN-Annual-Meeting

[$heff]

New Economy Portfolio Update..An early “ASCO” play near the bottom as we head into April. This stock which is GTXI is close to its bottom price. 52wk low is $1.31 and 52wk high is $7.24. Looking for it to bounce hard soon. GTXI won’t release data at ASCO but the CEO stated it would be in the ASCO timeframe. End of Phase II meeting for Enobosarm in Breast Cancer shortly after in June. The company on March 6th closed a private placement done by their chairman. http://yhoo.it/1gCx7Tk The offering was done at price $1.77. http://yhoo.it/1izmcdS . There is a high short position in the company of 28.3% of the float. I think some strong buying volume will cause the shorts to cover and this could move higher combined w/ the positive catalysts.

Will do a separate DD post here this evening.

Alert..bought GTXI at $1.85 in the Beginner Portfolio for a catalyst play into June. Company has plenty of upside here. It could see $3+ into June based on solid catalysts and the fact the company is well below its 52wk high with solid catalysts moving forward.

Disclaimer:..http://bit.ly/OlN9DB